Filter articles using the following links

2nd Annual Cell & Gene Therapy Congress, London, UK

European Society of Gene and Cell Therapy (ESGCT), Florence, Italy

GenSight Biologics reports its cash position as of September 30, 2016

European Association for Vision and Eye Research, EVER, Nice, France

Cell&Gene Meeting on the mesa, La Jolla (CA), USA

Cell&Gene Therapy Europe, Berlin, Germany

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie